Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2247 • ACR Convergence 2023
Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis
Leticia Leon¹, Dalifer Freites², Maria Rodriguez Laguna³, Cristina Martinez⁴, Esther Toledano⁴, Inmaculada Morado³, Benjamin Fernandez³ and lydia Abasolo², ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Spain, ⁴Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: The impact of gender on biological and targeted synthetic therapies (ts/bDMARDs) used in PsA patients has been scarce studied. Our main objective was to…
Abstract Number: PP05 • ACR Convergence 2023
Relief Redefined: A Patient’s Journey to Reducing the Impact of Her PsA Flare Ups
Caitlin West, Advocate, Coatesville, PA
Background/Purpose: I was diagnosed with Psoriatic Arthritis (PsA) ten years ago, at 25. I had been dealing with stiffness and chronic fatigue for most of…
Abstract Number: 0062 • ACR Convergence 2023
Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes
Alyssa Gilmore¹, Success Amaechi², Megan Hanlon³, Dumitru Anton⁴, Carl Orr⁵, Viviana Marzaioli⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Trinity College Dublin, Dublin, Ireland, ²Trinity College Dublin, Mullingar, Ireland, ³Molecular Rheumatology, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland
Background/Purpose: While Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) share many features, they are distinct in clinical presentation and molecular profile. As monocytes are crucial…
Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Ashmia Saif¹, Priyanka Dongare², Meghan Beard³, Yunhan Liao⁴, Xiaoyue Zhang⁴, Qingping Yao⁵ and Asha Patnaik⁶, ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University Hospital, Highland, NY, ³Stony Brook Southampton, Moriches, NY, ⁴Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁵Stony Brook University, Stony Brook, NY, ⁶Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…
Abstract Number: 0503 • ACR Convergence 2023
Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza², Smriti K Raychaudhuri³ and Abhijit Chaudhari⁴, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²University of California Davis, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA, ⁴UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…
Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Anirudh Subramanian Muralikrishnan¹, Barbara Dreo², Angelika Lackner¹, Rusmir Husic³, Florentine Moazedi-Fuerst³, Josef Hermann⁴, Philipp Bosch¹, Johannes Fessler¹, Jens Thiel⁵ and Martin Stradner¹, ¹Medical University of Graz, Graz, Austria, ²Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Meduni Graz, Graz, Austria, ⁴Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…
Abstract Number: 1388 • ACR Convergence 2023
Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
Ummugulsum Gazel¹, Kristen Noges², Burak Ayan², Gizem Ayan³, Olivier Brown¹, Andra Smith¹ and sibel aydin⁴, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey, ⁴University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Approximately 50% of PsA patients have persistent pain despite a well‐controlled inflammatory state, which has been attributed to non‐nociceptive pain and central sensitization. Enthesitis…
Abstract Number: 1426 • ACR Convergence 2023
Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
Dafna Gladman¹, William R Tillett², David Gruben³, Laura Coates⁴, Stefanie Hahne⁵ and Mikhail Volkov⁶, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Pharma GmbH, Berlin, Germany, ⁶Pfizer BV, Capelle aan den IJssel, Netherlands
Background/Purpose: PsA is a heterogeneous disease, and identifying clinical phenotypes may assist clinical decision making. Patients (pts) treated with advanced therapies demonstrate varying treatment responses.…
Abstract Number: 1640 • ACR Convergence 2023
Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
Rebecca Haberman¹, Sydney Catron¹, Yu Veronica Sui¹, Sarah Moussavi¹, Soumya Reddy², Eileen Lydon³, Andrea Neimann¹, Alexis R Ogdie⁴, Mariana Lazar¹ and Jose Scher⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³New York University, New York, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in psoriatic disease (PsD) therapeutics, treatment response remains suboptimal. Even in patients with psoriatic arthritis (PSA) that achieve seemingly controlled inflammation,…
Abstract Number: 1787 • ACR Convergence 2023
Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri², ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²VA Sacramento Medical Center, Mather, CA
Background/Purpose: In psoriatic arthritis (PsA) aberrant activation/migration of specific T cell subpopulations (Th17/Th9/MAIT cells) in the joint synovium induce synovial inflammation and pannus formation. Several…
Abstract Number: 2232 • ACR Convergence 2023
Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Dennis McGonagle¹, raja atreya², Maria Abreu³, James Krueger⁴, Kilian Eyerich⁵, Robert Bissonnette⁶, Kacey Sachen⁷, Carrie Greving⁷, Brian Stoveken⁸, Deepa Hammaker⁷, Kristin Leppard⁸, John Hartman⁸, Phuc Bao⁷, Eilyn Lacy⁸, Indra Sarabia⁷, Janise Deming⁷, Matthew Duprie⁸, Joseph Brown⁷, Christopher T Ritchlin⁹, Iain McInnes¹⁰, Matthieu Allez¹¹ and Anne Fourie⁷, ¹Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ²Erlangen University Hospital, Friedrich-Alexander-Univrsität Erlangen-Nürnberg, Erlangen, Germany, ³University of Miami, Leonard Miller School of Medicine, Miami, FL, ⁴The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, ⁵Medical Center, University of Freiburg; Karolinska Institute, Department of Medicine - Division of Dermatology and Venereology, Stockholm, Sweden, ⁶Innovaderm Research Inc, Medical Director, Montréal, QC, Canada, ⁷Janssen Research and Development, LLC, Immunology, San Diego, CA, ⁸Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁹University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Hôpital Saint-Louis, Université Paris Cité, Paris, France
Background/Purpose: Monoclonal antibodies (mAbs) targeting the interleukin (IL)-23p19 subunit are effective in treating psoriatic disease; however, their molecular attributes may translate to differences in clinical…
Abstract Number: 2248 • ACR Convergence 2023
Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
lydia Abasolo¹, Leticia Leon², Maria Rodriguez Laguna³, Esther Toledano⁴, Gloria Candelas³, Cristina Martinez⁴, Maria Paula Alvarez Hernandez³, Benjamin Fernandez³ and Dalifer Freites¹, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Spain, ⁴Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: In Psoriatic arthritis (PsA), patients who fail to respond to biologics and targeted synthetic therapies (ts/bDMARDs), switching to another ts/bDMARD should be considered. Failure…
Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Vanessa Patino-Lydia, Global Healthy Living Foundation, Hallandale, FL
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…
Abstract Number: 0161 • ACR Convergence 2023
Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Brigitte Michelsen¹, Mikkel Østergaard², Michael Nissen³, Adrian Ciurea⁴, Burkhard Moeller⁵, Lykke Ørnbjerg⁶, Jakub Zavada⁷, Bente Glintborg⁸, Alan MacDonald⁹, Karin Laas¹⁰, Dan Nordstrom¹¹, Bjorn Gudbjornsson¹², Florenzo Iannone¹³, Pasoon Hellamand¹⁴, Tore Kvien¹⁵, Ana Maria Rodrigues¹⁶, Catalin Codreanu¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Johan Karlsson Wallman²⁰, Jiri Vencovsky²¹, Anne Gitte Loft²², Maureen Heddle²³, Sigrid Vorobjov²⁴, Anna-Mari Hokkanen²⁵, Gerdur Maria Grondal²⁶, Marco Sebastiani²⁷, Marleen van de Sande²⁸, Eirik Kristianslund²⁹, Maria Jose Santos³⁰, Corina Mogosan³¹, Matija Tomsic³², Jose Federico Diaz-Gonzalez³³, Daniela Di Giuseppe³⁴ and Merete Hetland⁶, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ³Geneva University Hospitals, Geneva, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁹NHS Grampian, Aberdeen, United Kingdom, ¹⁰Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ¹⁷Center for Rheumatic Diseases, Bucharest, Romania, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lund University and Skåne University Hospital, Lund, Sweden, ²¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²²Aarhus University, Horsens, Denmark, ²³Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ²⁴National Institute for Health Development, Tallinn, Estonia, ²⁵Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁶Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²⁷Azienda Policlinico di Modena, Modena, Italy, ²⁸Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²⁹Diakonhjemmet Hospital, Oslo, Norway, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹University of Medicine and Pharmacy, Bucharest, Romania, ³²University Medical Centre Ljubljana; Universitiy of Ljubljana, Ljubliana, Slovenia, ³³Hospital Universitario de Canarias, La Laguna, Spain, ³⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…
Abstract Number: 0488 • ACR Convergence 2023
Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity
Nancy Shadick¹, Kumiko Schnock², Vivi Feather³, Ruogu Li², Jing Cui¹, Shivani Patel², Sabrina Goutier¹, Muibat Yussuff², Lourdes Perez-Chada², Michael Weinblatt⁴ and Joseph Merola⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Mass General Brigham, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patients with Psoriatic Arthritis (PsA) and Psoriasis (PsO) have an increased rate of work loss due to their disease compared the general population; however,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].